ALNY
Price
$300.83
Change
-$7.17 (-2.33%)
Updated
Jun 6 closing price
Capitalization
39.22B
54 days until earnings call
EXEL
Price
$43.03
Change
+$0.66 (+1.56%)
Updated
Jun 6 closing price
Capitalization
11.73B
66 days until earnings call
Interact to see
Advertisement

ALNY vs EXEL

Header iconALNY vs EXEL Comparison
Open Charts ALNY vs EXELBanner chart's image
Alnylam Pharmaceuticals
Price$300.83
Change-$7.17 (-2.33%)
Volume$954.85K
Capitalization39.22B
Exelixis
Price$43.03
Change+$0.66 (+1.56%)
Volume$2.34M
Capitalization11.73B
ALNY vs EXEL Comparison Chart
Loading...
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALNY vs. EXEL commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALNY is a Buy and EXEL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (ALNY: $300.83 vs. EXEL: $43.03)
Brand notoriety: ALNY: Not notable vs. EXEL: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALNY: 95% vs. EXEL: 76%
Market capitalization -- ALNY: $39.22B vs. EXEL: $11.73B
ALNY [@Biotechnology] is valued at $39.22B. EXEL’s [@Biotechnology] market capitalization is $11.73B. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALNY’s FA Score shows that 1 FA rating(s) are green whileEXEL’s FA Score has 1 green FA rating(s).

  • ALNY’s FA Score: 1 green, 4 red.
  • EXEL’s FA Score: 1 green, 4 red.
According to our system of comparison, EXEL is a better buy in the long-term than ALNY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALNY’s TA Score shows that 6 TA indicator(s) are bullish while EXEL’s TA Score has 5 bullish TA indicator(s).

  • ALNY’s TA Score: 6 bullish, 4 bearish.
  • EXEL’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ALNY is a better buy in the short-term than EXEL.

Price Growth

ALNY (@Biotechnology) experienced а -1.22% price change this week, while EXEL (@Biotechnology) price change was -0.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

ALNY is expected to report earnings on Jul 31, 2025.

EXEL is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALNY($39.2B) has a higher market cap than EXEL($11.7B). EXEL (29.219) and ALNY (27.844) have similar YTD gains . EXEL has higher annual earnings (EBITDA): 719M vs. ALNY (-152.58M). ALNY has more cash in the bank: 2.63B vs. EXEL (1.11B). EXEL has less debt than ALNY: EXEL (191M) vs ALNY (1.3B). ALNY has higher revenues than EXEL: ALNY (2.35B) vs EXEL (2.17B).
ALNYEXELALNY / EXEL
Capitalization39.2B11.7B335%
EBITDA-152.58M719M-21%
Gain YTD27.84429.21995%
P/E RatioN/A19.65-
Revenue2.35B2.17B108%
Total Cash2.63B1.11B237%
Total Debt1.3B191M682%
FUNDAMENTALS RATINGS
ALNY vs EXEL: Fundamental Ratings
ALNY
EXEL
OUTLOOK RATING
1..100
2167
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
73
Overvalued
PROFIT vs RISK RATING
1..100
2531
SMR RATING
1..100
10041
PRICE GROWTH RATING
1..100
3839
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
95n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EXEL's Valuation (73) in the Biotechnology industry is in the same range as ALNY (99). This means that EXEL’s stock grew similarly to ALNY’s over the last 12 months.

ALNY's Profit vs Risk Rating (25) in the Biotechnology industry is in the same range as EXEL (31). This means that ALNY’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's SMR Rating (41) in the Biotechnology industry is somewhat better than the same rating for ALNY (100). This means that EXEL’s stock grew somewhat faster than ALNY’s over the last 12 months.

ALNY's Price Growth Rating (38) in the Biotechnology industry is in the same range as EXEL (39). This means that ALNY’s stock grew similarly to EXEL’s over the last 12 months.

EXEL's P/E Growth Rating (92) in the Biotechnology industry is in the same range as ALNY (100). This means that EXEL’s stock grew similarly to ALNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALNYEXEL
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
72%
Bullish Trend 1 day ago
70%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
69%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
59%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
64%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 1 day ago
65%
Advances
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 1 day ago
65%
Declines
ODDS (%)
Bearish Trend 29 days ago
67%
Bearish Trend 3 days ago
63%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
57%
Aroon
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
ALNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EXEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DLHAX23.170.32
+1.40%
Macquarie Healthcare A
RWGIX5.12N/A
N/A
Wedgewood Institutional
IEMKX10.66N/A
N/A
Voya Multi-Manager Emerging Markets Eq R
OTIIX55.20N/A
N/A
T. Rowe Price Small-Cap Stock I
TSOPX15.06N/A
N/A
Nuveen International Res Eq Prmr

EXEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, EXEL has been loosely correlated with ALNY. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if EXEL jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EXEL
1D Price
Change %
EXEL100%
+1.56%
ALNY - EXEL
34%
Loosely correlated
-2.33%
JAZZ - EXEL
34%
Loosely correlated
+2.14%
TECH - EXEL
33%
Poorly correlated
+0.79%
MRSN - EXEL
32%
Poorly correlated
+4.78%
ORMP - EXEL
32%
Poorly correlated
+3.26%
More